Member Info for semantic

I.e. nobody is reading this stuff except us and to us it is inconsequential

If this thread is representative of the shareholder base, it is clear that only a tiny number of familiar names are active (verbally not financially) and that none of us have the firepower to move the share price away from its current level. Personally I thought the Interims were interesting but nobody acted on them either way, and even the quality of discussion here was wanting. It seems the assumption that the 'market' is looking and taking notice is just plain wrong

Paladin, while I am reluctant to appear for the defence of TB, the facts are that the TB/Fab shareholding was reinstated at the maximum 29% level after the placing which arguably could never have happened with that support. as I think they took most of it, and couldn't have participated at all without the headroom which came from sales prior.

My conclusion. Nobody is looking other private invstors waiting for the next RNS to provide an opportunity to bail out, nobody other than insiders have any real understanding of the complex and difficult technologies being undertaken, or any understanding of the potential significance of the trial, the FDA fast tracking, orphan drug designation etc. If truly amazing news were released, with a market cap of £2.5m, only private investors who are locked in will see it, and then only to bail.

Paladin, you may have a point but it doesn't explain the tiny trades over past months. In reality, surely anyone looking at this company in the last few months would have read the many published documents and made a decision to buy or not. TB actions are the possible preoccupation of some existing shareholders but how would new buyers have any reason to be put off by sales at say 3p, 4p, months ago when the share price is now 1.3p. It makes no sense

There does seem to be a version of fantasy football operating in many of these threads. Learned and intelligent discussions occasionally, ill-informed paranoid rants often, spades of bonhomie even, but all the time the reality is that tiny parcels of shares of near insignificant value are punted around in a disconnected universe, and in another disconnected universe the market cap of the company moves a few hundred thousand up and down. Can any of this be taken seriously?

I find it unfathomable that there have been 5 trades so far today with a total value of £143.91p. I mean why bother? Some of you might be able to explain the phenomenon of inconsequential trades of which there are many in this share, though would anyone really admit it - please share your thoughts?

Just as I posted my message, there was a further order, this time 150k, nice round lots, it could mean something or it could mean nothing or something in between..

An unusual thing. A 415k order at the full ask of 1.2p. £5k value order - unusual if only for that reason. Not a scrappy penny punter but neither the action of a clear and serious committed and purposeful newcomer. The US is closed today for a public holiday which points to a local buyer, but what do I know?

This is not at all like Covid. It’s not really clear that people spread it before symptoms appear.

Symptoms are very obvious. This will be dealt with by isolating outbreaks

The impression I get is that the Board are not interested in a bid because even at 1000% premium it would be perceived as peanuts. Remember the main insider shareholders have already seen a share price of 20 x current and were apparently unmoved. I think it is difficult to impossible to comprehend what is possible here. Presumably any bidder would be bidding because they can see significant upside at that bid price, but the Board would already be aware of the potential before any bidder. The 29.9% negative control in the TEB/FAB concert party is there, unchanged for a reason and my guess is that after all these years of blood sweat and tears they are going to see it through to whatever is the resolution. I see this as a positive personally. This situation reminds me of how the normal rules and expectations break down, as in physics. "The laws of physics contradict each other and result in illogical math like division by zero in black holes. Physics laws are not made to deal with infinitely strong time-space traps and matter and gravity in an infinitely small space of a gravity trap" In other words, normal rules don't apply here

Seconds after I posted this a shareholder sold £1500 of shares and knocked £100k off the market cap.

a day after the interims, one trade of £200. clearly, whatever the share price, it isn't the correct price. either it is too high or to low after new information yesterday, if the market is efficient the 'market' (as some of you believe) has, after much learned head scratching about revenue increases and progress on different projects, and adjusted for worries about teb, decided that the updated value of the company is exactly the same as before. the opportunity here may derive from the virtual invisibility of the company, and the consequent mis-pricing of the shares. a question for market whisperers - is the share price is where it is because "the market knows something" or is that shown at last to be obvious *******s because "the market" though having been updated clearly doesn't exist as a concept as many of you believe

Thank you Tyke (why am I thanking you - because I am polite and know the conventions even though I don't share them). Personally I don't have 'weekends' and have no need for them, choosing to do what I want pretty much every day. This week and into the 'weekend' the IQAI share price has been "as idle as a painted ship on a painted ocean" even though we know that beneath the hull, intense and important activity continues without pause. Let's pray for wind and hope we avoid the fate of the Ancient Mariner

A quick google search also indicated that no patients expired on either arm of the study (placebo or treated) and this is a very slow growing type of (rare) tumor.

There also appears to be some harsh(er) toxicity than GaM. See below.

https://medcitynews.com/2024/08/brain-cancer-glioma-fda-approval-servier-pharmaceuticals-vorasidenib-voranigo/

No deaths were reported in either arm. Progressive disease was reported in 28% of patients in the study drug group and in 54% of participants in the placebo arm. The efficacy analysis was supported by the measure of time to the next therapeutic intervention. This time was not reached for the study drug arm and was 17.8 months for the placebo arm. Results from the pivotal study were presented last year during the annual meeting of the American Society of Clinical Oncology and published in the New England Journal of Medicine.

The recommended Voranigo dose for adults is a 40 mg tablet once daily until the disease progresses or toxicity becomes unacceptable. For adolescents, the drug is dosed according to patient weight. The most common adverse reactions reported in the study include fatigue, headache, muscle pain, and diarrhea. Liver toxicity is another risk of the drug and the label and directs clinicians to monitor patients’ liver function.

Servier said the drug will cost $39,881 a month, which amounts to $478,572 a year. The company added that it is working with commercial and government payers, and it expects Voranigo will receive strong coverage based on the strong clinical data that supported its regulatory approval.

The drug is approved for grade 2 gliomas with IDH1/2 mutations only. This approval is for a low-grade brain tumor which has a better prognosis and different biology than GBM (glioblastoma) tumors being treated in our Phase 1 trial. GBM is a high-grade (the highest possible grade) brain tumor. In fact, patients with low-grade gliomas i.e. Grade 2 gliomas with IDH mutations are excluded from our study.

Tyke you asked me to share my thoughts on the Company. There are three key variables, inputs (costs) outputs (sales) but the most important variable for this business is time. People are worry that there has been "no news", but every day that passes is either a step nearer to news and/or a step in the progression of the main projects. Imagine that there was a news blackout for two years, or five even, How likely is it that two years of development would have increased the value of the business compared with a reduction, and what are the odds that five years of working literally 24x7 would produce a diminution in value as opposed to an increase. The worst outcome for waiting two years would be zero, the company could be insolvent. But that is the absolute worst that could happen. If you then consider the range of positive outcomes, there is literally no measurable limit, it is a matter of probability weighted conjecture, i.e. your guess is as good as mine but how much does the current share price discount all the possible outcomes?

Tyke wishes people a '"good weekend" most Fridays. The implication is its a wrap until Monday when the "week" begins again. I suspect that most of the important activities of the IB/IQAI team do not cease or slow down at the weekend, and rarely even any part of any 24 hour day. Weekends are for wimps

Bertie re IB/IQAI

IB is the sole trading subsidiary of IQAI, in this sense it *is* IB. Furthermore the significant amounts of capital which have been raised over the years have gone to develop the IB business apart from the mandatory costs on maintaining a Standard listing. £100k is a relatively small sum for a CEO of a company of this status, and having a CEO for a quoted company is obligatory. IB's 'superlative skills' are are deployed and developed and discussed at the PLC level - Mike Schmainda is after all a director of IQAI. The separation you describe does not exist in reality